CDKN2A/P16 expression in mycosis fungoides

被引：0
|
作者：
Fargnoli, MC
Chimenti, S
Stanta, G
Bonin, S
Amantea, A
Felli, A
Peris, K
机构：
[1] UNIV AQUILA,DEPT DERMATOL,I-67100 LAQUILA,ITALY
[2] UNIV TRIESTE,DEPT PATHOL,I-34127 TRIESTE,ITALY
[3] INT CTR GENET ENGN & BIOTECHNOL PADRICIANO,TRIESTE,ITALY
[4] IRCCS,IST SAN GALLICANO,ROME,ITALY
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 1997年 / 109卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：487 / 487
页数：1
相关论文
共 50 条
  • [31] Loss of p16 (CDKN2A) Expression Is Rare in Dedifferentiated Liposarcoma and Does Not Promote Tumor Progression
    Kang, Y.
    Horvai, A. E.
    MODERN PATHOLOGY, 2014, 27 : 19A - 19A
  • [32] CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations
    Nielsen, GP
    Burns, KL
    Rosenberg, AE
    Louis, DN
    AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (01): : 159 - 163
  • [33] CDKN2A and MTAP Deletions in Peritoneal Mesotheliomas: Correlation with Loss of p16 Protein Expression and Survival
    Krasinskas, A. M.
    Bartlett, D.
    Cieply, K.
    Dacic, S.
    MODERN PATHOLOGY, 2009, 22 : 136A - 136A
  • [34] CDKN2A and MTAP Deletions in Peritoneal Mesotheliomas: Correlation with Loss of p16 Protein Expression and Survival
    Krasinskas, A. M.
    Bartlett, D.
    Cieply, K.
    Dacic, S.
    LABORATORY INVESTIGATION, 2009, 89 : 136A - 136A
  • [35] Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions
    Harms, Paul W.
    Hocker, Thomas L.
    Zhao, Lili
    Chan, May P.
    Andea, Aleodor A.
    Wang, Min
    Harms, Kelly L.
    Wang, Michael L.
    Carskadon, Shannon
    Palanisamy, Nallasivam
    Fullen, Douglas R.
    HUMAN PATHOLOGY, 2016, 58 : 152 - 160
  • [36] MTAP and p16 IHC as Markers for CDKN2A/B Loss in Meningiomas
    Ozkizilkaya, Hanim I.
    Vinocha, Anjali
    Dono, Antonio
    Ogunbona, Oluwaseun Basit
    Toruner, Gokce A.
    Aung, Phyu P.
    Kamiya Matsuoka, Carlos
    Esquenazi, Yoshua
    Demonte, Franco
    Ballester, Leomar Y.
    CANCERS, 2024, 16 (19)
  • [37] Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma
    Cottone, Lucia
    Eden, Nadia
    Usher, Inga
    Lombard, Patrick
    Ye, Hongtao
    Ligammari, Lorena
    Lindsay, Daniel
    Brandner, Sebastian
    Pizem, Joze
    Pillay, Nischalan
    Tirabosco, Roberto
    Amary, Fernanda
    Flanagan, Adrienne M.
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2020, 6 (02): : 113 - 123
  • [38] CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure
    Kettunen, Eeva
    Savukoski, Sauli
    Salmenkivi, Kaisa
    Bohling, Tom
    Vanhala, Esa
    Kuosma, Eeva
    Anttila, Sisko
    Wolff, Henrik
    BMC CANCER, 2019, 19 (1)
  • [39] EVALUATION OF P16 AND MTAP IMMUNOHISTOCHEMICAL EXPRESSION AS SURROGATE MARKERS OF CDKN2A/B DELETION IN MENINGIOMAS
    Ricci, A. A.
    Tampieri, C.
    Nozzoli, F.
    Buccoliero, A. M.
    Mangherini, L.
    di Cantogno, L. Verdun
    Osella-Abate, S.
    Pellerino, A.
    Bruno, F.
    Ruda, R.
    Garbossa, D.
    Massi, D.
    Cassoni, P.
    Bertero, L.
    NEURO-ONCOLOGY, 2023, 25 : 123 - 123
  • [40] Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma
    Vizcaino, M. Adelita
    Giannini, Caterina
    Vaubel, Rachael A.
    Nguyen, Aivi T.
    Trejo-Lopez, Jorge A.
    Raghunathan, Aditya
    Jenkins, Sarah M.
    Jenkins, Robert B.
    Mendoza, Cinthya J. Zepeda
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2024, 83 (12): : 1003 - 1009
12345